PROG News and Press, Progenity Inc. From 07/27/23

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap™ tar...

SAN DIEGO, July 17, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company...

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora’s form...

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap&#x...

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Re...

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced registered direct offering of an ...

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale...

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platfo...

Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform is advancing both internally and with pharma collaborator’s molecul...

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial mar...